Hawthorne, New York, United States:
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro,” or the
“Company”), today announced that in view of the unusual market activity
in the Company’s stock, the New York Stock Exchange (“NYSE”) has
contacted the Company in accordance with its usual practice. The NYSE
has asked the Company to respond by press release to the unusual
The Company’s policy is not to comment on unusual market activity,
rumors or speculation.
Taro Pharmaceutical Industries Ltd. is a multinational, science-based
pharmaceutical company, dedicated to meeting the needs of its customers
through the discovery, development, manufacturing and marketing of the
highest quality healthcare products. For further information on Taro
Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.
SAFE HARBOR STATEMENTS
Certain statements in this press release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995.
These statements include, but are not limited
to, statements that do not describe historical facts and statements that
refer or relate to events or circumstances Taro “estimates,” “believes,”
or “expects” to happen or similar language.
statements in this press release are based on Taro’s current
expectations and are made only as of the date of this press release and
involve certain risks and uncertainties that could cause actual results
to differ materially from future results that may be expressed or
implied by such forward-looking statements.
Unless required by
law, Taro undertakes no obligations to update, change or revise any
forward-looking statement, whether as a result of new information,
additional or subsequent developments or otherwise.
William J. Coote, 914-345-9001